Study Group: Physicians who Treat Gaucher's Disease (US)(?)

These strategies are running out of steam as insurers, and even the general public, are catching on.  Most insurers will only pay for generic modafanil, and these new versions will not sell as much as they would have even 5 years ago.  The abuse potential of the drug may help, as brand-name...

Because equivalent results were shown, there will be no change in stent placement volumes.

The idea that people will always buy prescription and OTC drugs and will go to the physician and dentist, no matter what the economic conditions in the country, is, in my opinion, erroneous.  People's first priorities are getting to work (requiring gas), food, and shelter.  The most money...

Drugs are released to the market without adequate study, then, after around 70 to 100 patient deaths due to the drug are reported, the drug is pulled from the market.  Getting in front of this "problem" would improve the safety of our drug supply.

Drug company (Roche) retaliates against an agency that speaks the truth about their chemical - that it's cost is not worth the minimal benefit.  This will become more common as time goes on, even here in the bastion of capitalism.